Lee Schwartzberg, MD, FACP, advocates for the increased use of biosimilars in oncology and discusses the benefits of these agents for patients and providers.
Kurt W. Tauer, MD, FACP, discusses the expansion of subtyping in breast cancer.
Gregory Vidal, MD, PhD, assistant professor, Department of Hematology/Oncology, The University of Tennessee Health Science Center, and medical oncologist, West Cancer Center, discusses the potential use of CDK4/6 inhibitors in HER2-positive breast cancer.
Gregory Vidal, MD, PhD, discusses how the field will determine which trastuzumab (Herceptin) biosimilar to prescribe in clinical practice.
Experts from West Cancer Center highlighted the exciting research being conducted at their institution.
Bradley G. Somer, MD, discusses the importance of taking a proactive approach towards the use of biosimilars in oncology.
Lee S. Schwartzberg, MD, FACP, discusses the development and approval process for biosimilars and explains how their availability could drive down out-of-pocket costs for patients.
Bradley G. Somer, MD, discusses the education surrounding biosimilars in oncology.